Roth Lifts PT on Stemline (STML) to $62; Sees 'Pivotal' Year in 2014
Tweet Send to a Friend
Roth Capital raises its target price on Stemline Therapeutics, Inc. (Nasdaq: STML) from $55 to $62 and maintains its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
